PPBT (Purple Biotech) Stock Based Compensation: $0.31 Mil (TTM As of Mar. 2026)


PPBT Purple Biotech Ltd PPBT
19 GF Score
Price $1.57
! 2 Warning Signs
View Full Analysis

What is Purple Biotech Stock Based Compensation?

Purple Biotech PPBT -4.01% 19 Stock Based Compensation is $0.31 Mil as of Mar. 2026. GuruFocus rates PPBT with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Purple Biotech's Stock Based Compensation for the three months ended in Mar. 2026 was $0.09 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $0.31 Mil.

Purple Biotech Stock Based Compensation Related Terms

Purple Biotech Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Purple Biotech's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Purple Biotech Stock Based Compensation Chart

Purple Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.08 2.41 1.88 0.58 0.31

Purple Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.06 0.20 -0.04 0.09
PPBT
19GF Score
Purple Biotech Ltd PPBT
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Purple Biotech Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.31 Mil.

What does a Stock Based Compensation of $0.31 Mil mean?
Purple Biotech (PPBT) has a Stock Based Compensation of $0.31 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Purple Biotech and its competitors.
Is Purple Biotech's Stock Based Compensation too high?
Purple Biotech's current Stock Based Compensation is $0.31 Mil. Overall, Purple Biotech has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Purple Biotech's Stock Based Compensation compare to VRTX and REGN?
Purple Biotech's Stock Based Compensation of $0.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Purple Biotech and its competitors. Purple Biotech's current Stock Based Compensation is $0.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Purple Biotech stock overvalued right now?
Purple Biotech (PPBT) has a current Stock Based Compensation of $0.31 Mil. The current Stock Based Compensation is $0.31 Mil. Purple Biotech's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Purple Biotech (PPBT), the current Stock Based Compensation is $0.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Purple Biotech Business Description

Other Exchanges PPBT:Israel
Address 4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
19GF Score

Get the complete analysis for PPBT

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.57
Price